ASH 2022 | Phase Ib trial of entinostat in combination with pembrolizumab in R/R MDS or AML
Jan Bewersdorf
• 11 Dec 2022
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, shares the findings of a Phase Ib study evaluating the histone deacetylase (HDACi) entinostat in combination with pembrolizumab in patients with relapsed/refractory (R/R) myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML; NCT02936752). Overall, the trial reported limited efficacy for this novel treatment combination. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
